language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
IARTIART

$12.09

-0.24
arrow_drop_down1.95%
Current Market·update12 Nov 2025 21:00

$12.08

-0.01
arrow_drop_down0.08%
Pre-market·update13 Nov 2025 11:48
Day's Range
12.07-12.73
52-week Range
10.87-27.13

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-10-30
Next Earnings TimeBefore Market Open
Volume1.1M
Average Volume 30d1.19M

AI IART Summary

Powered by LiveAI
💰
-56
Valuation (P/E Ratio)
Negative P/E due to recent net loss
📈
-1.204
EPS Growth (YoY)
Significant decline in EPS
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Neutral
65

Integra LifeSciences Holdings Corporation shows mixed signals. While there are positive thematic elements, current fundamental and technical indicators suggest a neutral stance, requiring careful consideration of recent performance trends and upcoming earnings.

Moderate

Thematic

70

Integra LifeSciences operates in the medical technology sector, which benefits from an aging global population and increasing demand for advanced medical solutions. However, its specific product focus might face competition and evolving healthcare regulations.

Neutral

Fundamental

60

The company's recent financial performance shows declining revenue and net losses, impacting profitability and valuation metrics. Debt levels have increased, and free cash flow has been volatile.

Neutral

Technical

60

The stock price is trading below its 52-week range and has experienced significant declines over the past year. Current technical indicators are mixed, with some suggesting potential for a short-term bounce but overall trend remaining bearish.

FactorScore
Aging Global Population85
Healthcare Innovation75
Competitive Landscape55
Regulatory Environment60
Economic Sensitivity65
FactorScore
Valuation60
Profitability20
Growth60
Balance Sheet Health50
Cash Flow40
FactorScore
Trend Analysis30
Momentum50
Support & Resistance65
Moving Averages40
Volume Confirmation70

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Positive EPS Surprise

The company has a history of beating EPS estimates, with recent quarters showing positive surprises (e.g., +13.34% in Q1 2025, +5.28% in Q4 2024).

Valuation chevron_right

Attractive Price-to-Sales Ratio

The Price-to-Sales (PS) ratio of 0.8 for TTM suggests the company is valued relatively low compared to its revenue.

Show More 🔒
thumb_down

Bearish Points (8)

Earnings Performance chevron_right

Negative EPS Growth

EPS TTM is negative (-0.38), indicating the company is currently unprofitable on a per-share basis over the last twelve months.

Valuation Risk chevron_right

High Price-to-Sales for Negative Earnings

Despite a low PS ratio of 0.8, the company has a negative TTM net income, resulting in a very high (or negative) P/E ratio, indicating it's not currently a value investment based on earnings.

Show More 🔒

Calendar

July 2025

31

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.46

A: $0.43

L: $0.42

H: 399.08M

A: 395.06M

L: 386.40M

Profile

Employees (FY)4.4K
ISINUS4579852082
FIGI-

Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Seasonals

2025
2024
2023
2022
2021

Price Target

15.88 USD

The 39 analysts offering 1 year price forecasts for IART have a max estimate of 30.00 and a min estimate of 10.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
59.1M (76.02%)
Closely held shares
18.6M (23.98%)
77.7M
Free Float shares
59.1M (76.02%)
Closely held shares
18.6M (23.98%)

Capital Structure

Market cap
987.72M
Debt
1.98B
Minority interest
0.00
Cash & equivalents
246.38M
Enterprise value
2.73B

Valuation - Summary

Market Cap
988M
Net income
-16.6M(-1.68%)
Revenue
1.21B(122.11%)
988M
Market Cap
988M
Net income
-16.6M(-1.68%)
Revenue
1.21B(122.11%)
Price to earning ratio (P/E)-59.70x
Price to sales ratio (P/S)0.80x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
1.61B
COGS
728.47M
Gross Profit
882.06M
OpEx
853.65M
Operating Income
28.41M
Other & Taxes
35.35M
Net Income
-6.94M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒